MedPath

Visualization of the Extrahepatic biliaRy Tree Trial

Not Applicable
Conditions
Choledocholithiasis
Cholecystolithiasis
Acute Cholangitis
Gallbladder Diseases
Cholecystitis, Acute
Gallstone Pancreatitis
Biliary Tract Diseases
Digestive System Disease
Calculi
Pathological Conditions, Anatomical
Interventions
Procedure: Laparoscopic Cholecystectomy with Fluorescent Cholangiography
Procedure: Laparoscopic Cholecystectomy with White Light Imaging
Registration Number
NCT04922528
Lead Sponsor
University of British Columbia
Brief Summary

This study is a prospective randomized controlled trial evaluating the use of a fluorescent dye, indocyanine green (ICG), in the identification of important bile duct anatomy during emergent same-admission cholecystectomy. Participants will be randomized into either the control arm, which uses the standard of care white light during laparoscopy or the intervention arm, which will use ICG fluorescent cholangiography as an adjunct to white light to visualize the biliary anatomy. The investigators hypothesize that the use of fluorescent cholangiography will increase the rates of identification of important biliary anatomy during laparoscopic cholecystectomy. The effectiveness, feasibility, and safety will be compared between the two groups using a post-operative survey form the surgeons will complete prior to exiting the operating room.

Detailed Description

Near-infrared fluorescent imaging techniques have shown promise in aiding to delineate and visualize extrahepatic biliary structures. Indocyanine green (ICG) is a water-soluble fluorescent dye that has been shown to improve visualization of biliary anatomy under fluorescent cholangiography. The standard of care for many acute biliary disease conditions, such as acute cholecystitis, remains early laparoscopic cholecystectomy. Even though real-time fluorescent cholangiography using ICG has the potential to enhance the visualization of biliary structures and anatomy, and therefore reduce the risk for bile duct injury, the majority of the studies published to date exclude acute biliary disease patients. The pathophysiology of acute biliary disease processes is associated with inflammation and adhesions that increase the challenge of achieving a critical view of safety. The investigators propose that using ICG and fluorescent cholangiography near-infrared imaging techniques as an adjunct in acute care laparoscopic cholecystectomies has the potential to help mitigate the increased risk of bile duct injury by increasing extrahepatic biliary structure detection and surgeon confidence.

Eligible patients will be identified through their initial clinical evaluation, which will be verified by the patient's primary surgeon. If and once a patient has been confirmed as eligible, the surgeon or designate will introduce the clinical trial design in detail. If after being introduced to the study and having had the opportunity to ask questions, the patient is willing to participate, the patient will be asked to review and sign the informed consent document.

Upon entry into the clinical trial, the allocation sequence will be generated using a block randomization schema with computer-generated random numbers in a 1:1 ratio, with block sizes of 4 by a co-investigator with no clinical involvement in the trial. The same co-investigator will prepare sequentially numbered, opaque, sealed and stapled envelopes and stored them in a locked cabinet in the operating room control desk. Each envelope contained instructions for the arm the participant had been randomly assigned to, either treatment (ICG cholangiography) or control (standard white light only) arms. After the research team member has obtained the participant's consent, the surgeon or designates will obtain the next consecutively numbered envelope and proceed to open it after the patient is anesthetized and prior to beginning the surgery.

The patient will be blinded to the result of the randomization until after surgery as the envelope will be opened only after the patient has received their general anesthetic. No blinding of the surgical team, research team members or outcomes assessors will be used in this study given the procedural nature and acute condition of the patients included.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
340
Inclusion Criteria
  • Admission or consultation by the Acute Care Surgery (ACS) service
  • Diagnosis of acute biliary disease requiring index laparoscopic cholecystectomy
  • Diagnoses of acute cholangitis, choledocholithiasis, and gall stone pancreatitis may be included. However, they must have cleared ducts confirmed via endoscopic ultrasound, ultrasound, ERCP, and/or laboratory investigations.
  • Ability to understand and follow study procedures and protocols, and provide signed informed consent.
Exclusion Criteria
  • Female patients who are pregnant or currently breastfeeding
  • Known pre-existing liver disease, including cirrhosis
  • Known allergy to iodine or shellfish
  • Known allergy to indocyanine green (ICG)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Near-Infrared Fluorescence CholangiographyLaparoscopic Cholecystectomy with Fluorescent CholangiographyStandard laparoscopic cholecystectomy completed with a combination of white light imaging and near-Infrared fluorescence cholangiography after administering 5 mg of a 25 mg/10 mL solution of indocyanine green (ICG) intravenously prior to the operation
White Light ImagingLaparoscopic Cholecystectomy with White Light ImagingStandard laparoscopic cholecystectomy completed with only standard white light imaging only
Near-Infrared Fluorescence CholangiographyLaparoscopic Cholecystectomy with White Light ImagingStandard laparoscopic cholecystectomy completed with a combination of white light imaging and near-Infrared fluorescence cholangiography after administering 5 mg of a 25 mg/10 mL solution of indocyanine green (ICG) intravenously prior to the operation
Primary Outcome Measures
NameTimeMethod
Detection rate of extrahepatic biliary structuresIntraoperatively

The extrahepatic biliary structures which we will be assessing the identification of include: Cystic Duct (CD), Right Hepatic Duct (RHD), Common Hepatic Duct (CHD), Common Bile Duct (CBD), Cystic Duct - Gall Bladder junction (CD-GB), and Cystic Duct - Common Bile Duct junction (CD-CBD).

Secondary Outcome Measures
NameTimeMethod
Operative timeIntraoperatively

From the time of opening the skin to the time of closure.

Operative successIntraoperatively

Rates of laparoscopic subtotal cholecystectomy and laparoscopic cholecystostomy tube placement.

Rates of conversionIntraoperatively

Rate of conversion to open cholecystectomy.

Surgeon satisfactionThrough participant discharge, an average of 1 week

Operating surgeons satisfaction (as rated by post-procedural survey) with the utility and feasibility of the modality.

Trial Locations

Locations (1)

Vancouver General Hospital

🇨🇦

Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath